Amgen Inc. (AMGN) Stock Price & How to Invest

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

The financial picture as of October 2026 is steady growth with strong cash generation. Trailing revenue reached about ~$38.1 billion, with an operating margin near 36% and net income of ~$8.7 billion. In Q2 2026 (the quarter ended June 30), revenue rose about 9.5% year over year to ~$10.05 billion and adjusted EPS of $6.29 beat the ~$5.62 consensus, the fourth consecutive quarter of beats. The stock closed at $436 on October 16, 2026, up about 33.1% year to date and 47.4% over one year, near the top of its 52-week range of $288 to $447.

Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition left Amgen with about ~$57 billion of total debt against ~$14 billion of cash as of mid-2026. After a 33% year-to-date gain, the share price of $436 sits above the ~$395 average analyst target, and consensus expects only about 5% EPS growth in 2026 and 6% in 2027, so the valuation now assumes more than the near-term numbers show. Litigation, manufacturing, and safety risks are inherent to the industry.

29 analysts publish price targets on AMGN, averaging $394.98 against a $432.49 price as of October 2026, or -8.7%. The published targets run from $225.00 to $500.00, a moderate spread, and the ratings split 12 buy, 17 hold, 5 sell. Over the last six months there have been 5 raises and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AMGN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Amgen Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Rare disease and Horizon assets. The Horizon Therapeutics acquisition added higher-growth rare-disease drugs such as Tepezza and Krystexxa, diversifying Amgen away from older, slower-growing franchises and giving it newer products with patent runway and pricing power in specialty markets. The most optimistic published target, $500.00, assumes this works close to its best case.

The case against. Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. The most pessimistic target, $225.00, is roughly what AMGN is worth if this bites instead.

Read the full bull and bear case on AMGN, including what would have to change to break either one. Walnut is not an investment adviser.

No. Amgen Inc. (AMGN) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Amgen Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$38.1 billion
• Revenue growth (Q2 2026, YoY): ~9.5%
• Operating margin: ~36%
• Net income (TTM): ~$8.7 billion
• P/E (trailing / forward): ~27x / ~18x
• Dividend yield: ~2.3% (~$10.08 per year)
• Market cap: ~$236 billion
• Total debt / cash: ~$57 billion / ~$14 billion

As of October 16, 2026, Amgen trades at about 27x trailing GAAP earnings and about 18x forward earnings, with EV/EBITDA near 16x, a rerating from early 2026 after the shares gained about a third. The dividend yield has fallen to about 2.3% as the price rose. Consensus for the Q3 2026 report on November 3 is adjusted EPS of ~$5.76 on ~$10.06 billion of revenue; the 29 analysts covering the stock have an average target of about $395, below the current price.

If you want AMGN exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses AMGN naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to AMGN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AMGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (DIVO, UDOW, SCHD), which spreads the position across many companies. Or build it into a focused thematic portfolio, so AMGN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AMGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Amgen (AMGN) is a mature large-cap biopharma whose thesis rests on defending its biologics franchise, growing rare-disease and biosimilar revenue, and converting its pipeline (including obesity candidates) into new drugs. In a portfolio it behaves as a defensive, dividend-paying healthcare holding with patent-cliff and clinical-trial risk, rather than a high-growth position. In 2026 it has traded more like a winner than a defensive name, up about 47% over one year to mid-October, which has pushed the share price above the average analyst target ahead of Q3 results on November 3.

Whether AMGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AMGN a buy or a sell?, and where the stock could go from here in the AMGN stock forecast.

For income investors, whether AMGN pays a dividend and how the payout looks is covered in does AMGN pay a dividend? And to weigh AMGN against a peer, read the full side-by-side comparisons: AMGN vs LLY and AMGN vs PFE.